2015 Pharmaceuticals Small Molecule 
Dark Matter Blog
JANUARY 16, 2023
Our terra firma is small-molecule medicines. As we know, small molecules have been the mainstay of our pharmacopeia for several centuries and have, almost without exception, targeted proteins. This is why Arrakis set out in 2015 on an expedition to figure out how to develop small molecules that can target RNA.
Agency IQ
NOVEMBER 10, 2023
BY ALEXANDER GAFFNEY, MS, RAC | NOV 9, 2023 6:35 PM CST Background on CDER’s Office of Pharmaceutical Quality (OPQ) CDER’s Office of Pharmaceutical Quality became operational in January 2015, making it a still relatively recent addition to the agency. Read our analysis of a recent meeting focused on KASA here. ]
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JUNE 12, 2023
The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.
The Pharma Data
OCTOBER 25, 2020
Vatiquinone, developed from PTC’s Bio-e platform, is an investigational oral small molecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways underpinning many neurological disease pathologies, including epilepsy. 2015; Chevallier et al. Annals of Neurology.2015;
NIH Director's Blog: Drug Development
JULY 20, 2017
According to preliminary data from one Phase 1 and two Phase 2 clinical trials reported by Vertex Pharmaceuticals Inc., The next major milestone on the therapeutic pathway was the FDA’s approval in 2015 of Orkambi, a drug that combines ivacaftor with lumacaftor, the first “corrector”.
New Drug Approvals
SEPTEMBER 13, 2024
4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 18] In February 2015, Cerecor Inc. 21] In August 2017, it was announced that Cerecor had sold its rights to aticaprant to Janssen Pharmaceuticals. [22] nM vs. 24.0
Drug Target Review
JANUARY 5, 2024
The need to identify new drug targets and candidate active pharmaceutical ingredients (APIs) for treating PAM is increasing, as the geographic range of N. In particular, an ethylene glycol molecule (EDO403) was observed to be stably (and non-covalently) bound within the conventional nucleotide-binding pocket of Nf Ga7 ( Figure 2a ).
Expert insights. Personalized for you.
52 
Let's personalize your content